Global Drug Safety Solutions and Pharmacovigilance Market Set to Surge SignificaPosted by Rashi Pande on December 10th, 2019 The report outlines the competitive framework of the “Drug Safety Solutions and Pharmacovigilance Market” industry detailing the SWOT analysis and market share dominance of the prominent players. Global Card Personalization Equipment Market Report has released a new research Analysis & forecast 2019 to 2026 comprehensive of one or more factors covering regional opportunities, application landscape, product demand trends, and end-use portfolio of the industry over the forecast timeframe Global Drug Safety Solutions and Pharmacovigilance Market By Type (Software, Services), End Users (Biotechnology & Pharmaceuticals, Contract Research Organizations (CROS), Hospitals, KPOs/BPOs, Healthcare Providers), Distribution Channel (Direct Sales, Retail Sales), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) – Industry Trends and Forecast to 2026 Get Sample Report + All Related Graphs & Charts of Global Drug Safety Solutions and Pharmacovigilance Market @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-drug-safety-solutions-and-pharmacovigilance-market Some of the major players operating in global drug safety solutions and pharmacovigilance market are Pharmaceutical Product Development, LLC, Drug Safety Solutions Limited, C3i, Worldwide Clinical Trials, Bioclinica, United Biosource LLC, Ennov, AB Cube, Covance Inc., Accenture, PRA Health Sciences, Inc., Ergomed, IQVIA, Genpact, Cognizant, Parexel International Corporation, ArisGlobal, ICON plc, Oracle, Syneos Health among others.
Drug safety and pharmacovigilance was introduced 170 years ago for detection, assessment, and understanding of the drug action. Pharmacovigilance came into picture because the adverse reactions were observed, a young woman from the north of England recorded for ADRs reactions which lead to her death in January 1848. The experiment was discovered by Sir James Simpson that chloroform was a powerful anesthetic and for safer use it can be applied in the clinical practices. The cause of Hannah’s death was studied in order to understand what happened to Hannah as it was difficult to assess the cause of her death and it was assumed that probably lethal arrhythmia or pulmonary aspiration was the main reason leading to such unfavourable situation. Further, on 6 June 1960, the U.S. FDA was formed to ensure that the established drugs discovered and commercialized are pure and free of any contamination. Additionally, in 1961, the U.S. FDA also prohibited false therapeutic indications of drugs. Also, in 1961, European Pharmacovigilance was established after the tragedy of thalidomide which caused an adverse drug reaction named as phocomelia. In 1975, Practolol, a beta-receptor blocker agent, caused sclerosing peritonitis, and most recent is the event of 2007, where veralipride, a CNS depressant agent, caused so many ADRs such as anxiety, depression and movement disorders. Thus the medicines are made for life saving purpose, not for life threatening purpose. In the U.S., ADRs are among the top 10 causes of death, and in the U.K., it was observed that ADRs may cause 5,700 deaths per year. Segmentation: Global Drug Safety Solutions and Pharmacovigilance MarketAsia-Pacific drug safety solutions and pharmacovigilance market is segmented into three notable segments which are type, end user and distribution channel.
Recent Developments:
Like it? Share it!More by this author |